Clinical Trials Logo

Clinical Trial Summary

To compare the symptoms of patients who have a MIPG to the symptoms of patients who have a MITG.


Clinical Trial Description

Primary: Delineate the short-term appetite of patients who undergo minimally-invasive proximal gastrectomy (MIPG) and compare them with those of patients with gastric and gastroesophageal adenocarcinoma who undergo total gastrectomy (MITG). We hypothesize that MIPG is associated with better postoperative appetite levels compared to MITG, which would result in improved nutritional status and maintained body weight after surgery. Secondary: Assess patient-reported outcomes (PROs) and nutrition measures. We will use the MD Anderson Symptom Inventory Gastrointestinal Cancer Module (MDASI-GI) questionnaire with additional three experimental question items ("PRO questionnaire") to collect preoperative and postoperative patient-reported outcomes (PROs) of QoL and check fasting ghrelin levels to correlate them with reported appetite levels. We will also retrospectively investigate factors associated with improved QoL after surgery, safety of MIPG and MITG, and oncological outcomes after MIPG and MITG. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05205343
Study type Interventional
Source M.D. Anderson Cancer Center
Contact Naruhiko Ikoma, MD
Phone (832) 729-2675
Email [email protected]
Status Recruiting
Phase N/A
Start date May 11, 2022
Completion date May 31, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT04544046 - Supportive Oncology Care At Home RCT N/A
Not yet recruiting NCT04555304 - Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy Phase 2
Terminated NCT02669914 - MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors Phase 2
Active, not recruiting NCT04099641 - An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients Phase 2
Not yet recruiting NCT05427487 - Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours Phase 1
Not yet recruiting NCT05431738 - Anti-Migration System for Anti-reflux Oeso-gastric Stent (ANTIMIG) N/A
Recruiting NCT04385641 - Study on the Safety and Effectiveness of UCB-NK Cell Infusion in the Treatment of Advanced Gastric Cancer and Gastroesophageal Cancer N/A
Active, not recruiting NCT03165994 - APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers Phase 2
Recruiting NCT03321630 - A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies Phase 2
Active, not recruiting NCT03279237 - A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers Phase 1
Active, not recruiting NCT02853474 - Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy Phase 3
Active, not recruiting NCT03983954 - Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors Phase 1
Active, not recruiting NCT03647969 - Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer Phase 2
Recruiting NCT05122091 - Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma Phase 2
Not yet recruiting NCT05379972 - Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers Phase 2
Completed NCT03720678 - A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies Phase 1
Completed NCT02317991 - Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer Phase 2
Completed NCT02013154 - A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab Phase 1
Recruiting NCT05395052 - FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors Phase 1
Active, not recruiting NCT03490292 - Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer Phase 1/Phase 2